Sun Pharma has launched its global innovative drug, ILUMYA (Tildrakizumab), in India for the treatment of moderate-to-severe plaque psoriasis.

A novel biologic treatment, ILUMYA, has been widely endorsed by dermatologists in the US and worldwide for several years as an effective and safe treatment for moderate to severe plaque psoriasis.  

Kirti Ganorkar, Managing Director, Sun Pharma, said, “We are pleased to introduce this novel therapy in India from our global portfolio of innovative medicines. Already available in 35 countries, ILUMYA has consistently demonstrated significant and long-lasting skin clearance, beginning soon after initiation and sustained over years.”  

Dr. B. S. Chandrashekar, Chief Dermatologist and Managing Director at Cutis Academy of Cutaneous Sciences, Bengaluru, India, who was also an investigator in the India Phase 3 trial, highlighted the drug’s potential in improving the quality of life for psoriasis patients.

“Having been involved in the clinical development of Tildrakizumab in India, I am pleased to see its potential as an effective, safe, and long-lasting treatment for psoriasis. In the Phase-3 trial, tildrakizumab demonstrated significant improvements across all measures, with approximately 93.5% reduction in PASI score and pronounced skin clearance,” said Dr. Chandrashekar.

ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis. Patients living with moderate-to-severe plaque psoriasis need therapies they can use over long periods of time without loss of efficacy, and data shows that ILUMYA is a sustainable choice for patients over the long term.